Bio-techne Corp · NASDAQ:TECH

Bio-techne — Investor Presentation (January 2025)

15 slides from Bio-techne's investor presentation, Jan 14, 2025

Slide 2: Safe Harbor Cautionary Statements
Safe Harbor C A U T I O N A R Y S TAT E M E N T S This presentation contains “forward-looking Forward-looking statements are neither historical looking statement, whether written or oral, as statements” within the meaning of the federal facts nor assurances of future performance. a result of new inf
Slide 4: Differentiated Portfolio Serving High-Growth Markets
48-YEAR LEADER IN PROTEOMICS Differentiated Portfolio Headquarters Minneapolis, MN Serving High-Growth Markets Number of Employees Our Segments and Product Portfolio ~3,100 Instruments Services Protein Sciences: 9% 9% Royalties Worldwide Locations 2% 34 Instrument specific Proteins Antibodies Immuno
Slide 5: FY24 Revenue Breakdown ($1.2B)
FY24 Revenue Breakdown ($1.2B) Markets 12% Distributors Segments & Product End Markets 17% 50% Diagnostics Pharma/ 72% Protein Sciences Segment 28% Diagnostics & Spatial Biology Segment Biotech 21% Academia Spatial Biology 10% Precision Diagnostic 6% Tools Core Diagnostic Geographies Core RUO 12% Co
Slide 6: Foundation For Our Success
Durable and differentiated product portfolio Balanced exposure to established and emerging applications across high-growth end-markets Foundation For Our Portfolio leverage from leading protein & antibody content and capabilities Success Strong reputation and loyal customer base valuing quality and
Slide 7: Our Growth Vectors Capitalize on Megatrends
Our Growth Strategic Growth Vectors: Vectors Healthy 3 Enablement of Capitalize on Precision Aging Diagnostics Megatrends Precision Medicine Novel Therapeutic Approaches Development and 2 Manufacturing of Advanced AI-enabled Innovation Therapeutics Proteomic Interrogation at Scale Multiomic Insight
Slide 8: Differentiated Product Portfolio Creates Leverage
Differentiated Product Portfolio Creates Leverage Product Portfolio Our Strategic Growth Vectors Protein Sciences 1 Discovery of Novel Biological Insights Antibodies Proteomic Spatial Analytical Biology Proteins Antibodies Immunoassays Proteins & Small Instruments Molecules Immunoassays Proteomic Ce
Slide 9: Innovation Milestones in Our Growth Vectors
Innovation Milestones in Our Growth Vectors 1 2 3 Discovery of Novel Biological Insights Development & Manufacturing Enablement of of Advanced Therapeutics Precision Diagnostics Leo AI Designed Multiomic Spatial ProPak GMP ESR1 Instrument Reagents Biology Platform Reagents Kit Next-generation, Pipel
Slide 10: Driving Growth Despite Market Volatility
Driving Growth Despite Market Volatility Revenue ($M) Adj. Operating Income ($M) Operating Cash Flow ($M) +1% OG -10% 410 +18% 299 12% 1,137 1,159 14% 370 9% CAGR CAGR CAGR 254 244 182 714 FY19 FY23 FY24 FY19 FY23 FY24 FY19 FY23 FY24 © 2025 Bio-Techne®. All rights reserved. | 10
Slide 11: Strong Programmatic M&A Runway
Strong Programmatic M&A Runway Growth Vectors M&A Priorities • Analytical platforms Discovery of Novel • Product tuck-ins, applications expansions 11 Biological • Targeted innovation capabilities Insights • Opportunistic expansion Development & Manufacturing • Cell therapy workflow components and so
Slide 12: Portfolio Serves Critical Applications Within $28B Market
Portfolio Serves Critical Applications Within $28B Market D I A G N O S T I C S & S PAT I A L B I O L O G Y S E G M E N T Proteomic Analytics Spatial Biology PROTEIN SCIENCES SEGMENT Market Size Market Size Market Growth Rate Core Products Market Growth Rate Research Reagents, Assays & Dx Controls H
Slide 13: We are Committed to a Sustainable Future
We are Committed to a Sustainable Future P U B L I S H E D O U R F O U R T H C O R P O R AT E S U S TA I N A B I L I T Y R E P O R T Our People Advancing Science 43% female supervisor ~800 new products in 2024 & above globally ~8% of revenue invested in R&D Diverse and Inclusive 11 active Employee R
Slide 14: Key Takeaways
Key Takeaways The shown Megatrends create a flywheel for our three Strategic Growth Vectors Our differentiated proteomic core portfolio provides leverage across these Strategic Growth Vectors Together, We have a strong innovation and M&A pipeline to we unlock the expand portfolio and market position

Bio-Techne — Investor Presentation (January 2025) on 6ix

Bio-techne — Investor Presentation (January 2025)

Slide 1: Purposeful Innovation Leads to Better Answers

Slide 2: Safe Harbor Cautionary Statements

Slide 3: © 2025 Bio-Techne ® . All rights reserved. | 3

Slide 4: Differentiated Portfolio Serving High-Growth Markets

Slide 5: FY24 Revenue Breakdown ($1.2B)

Slide 6: Foundation For Our Success

Slide 7: Our Growth Vectors Capitalize on Megatrends

Slide 8: Differentiated Product Portfolio Creates Leverage

Slide 9: Innovation Milestones in Our Growth Vectors

Slide 10: Driving Growth Despite Market Volatility

Slide 11: Strong Programmatic M&A Runway

Slide 12: Portfolio Serves Critical Applications Within $28B Market

Slide 13: We are Committed to a Sustainable Future

Slide 14: Key Takeaways

Slide 15: © 2025 Bio-Techne ® . All rights reserved. | 15